

Poly Medicure Limited

Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110 020 (INDIA)
T: +91-11- 33550700, 47317000
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923



Date: 08th August, 2025

Scrip Code: - 531768

Scrip Code:- POLYMED

The Manager,
BSE Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Sub: Submission of Press Release for the Unaudited Financial Results (Standalone & Consolidated) for First Quarter ended on June 30, 2025

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release with respect to Unaudited Financial Results (Standalone & Consolidated) for First Quarter ended on June 30, 2025.

Request you to take the same on records.

Thanking You,
Yours Sincerely

For Poly Medicure Limited

Avinash Chandra
Company Secretary
M. No. A32270



Poly Medicure Limited Reports Q1 FY26 Results

Q1 FY26 Consolidated Revenue growth of 4.8% on a YoY basis; Q1 FY26 revenue growth in domestic market of 20.1%

Q1 FY26 Gross Profit of Rs 276 Crores reflecting a Gross Profit Margin of 68.4%, Gross Profit Margin expanded by 170BPS on a YoY basis

Q1 FY26 operating EBITDA Margin of 26.3% and PAT Margin of 20.9%

Capex spend of Rs 95 Crores till Q1 FY26, full year budget of Rs 250 Crores

New Delhi, August 08th, 2025: Poly Medicure Ltd. (NSE: POLYMED | BSE: 531768), India's leading Medical Device company with a dominant position in medical consumables market, today announced its unaudited consolidated and standalone financial results for the quarter ended on June 30th, 2025.

Key Financial Summary:

| Consolidated Rs. Crores | Q1 FY 2026 | Q1 FY 2025 | YoY Growth (%) |
|--------------------------------|--------------|--------------|----------------|
| Total Income | 444.9 | 401.7 | 10.7% |
| Gross Profit | 276.0 | 256.5 | 7.6% |
| <i>Gross Profit Margin</i> | 68.4% | 66.7% | 170BPS |
| Operating EBITDA | 106.1 | 103.8 | 2.1% |
| <i>Operating EBITDA Margin</i> | 26.3% | 27.0% | (70BPS) |
| Profit after Tax | 93.1 | 74.0 | 25.5% |
| <i>PAT Margin</i> | 20.9% | 18.4% | 250BPS |
| EPS - Basic | 9.2 | 7.7 | 18.8% |

Key Business Highlights:

- The Renal care business maintained its strong growth trajectory, delivering a robust 46.2% YoY growth, driven by expanded presence and sale of 130 dialysis machines between April and July 2025
- A total of **1350+ stents** were successfully implanted between April to July 2025, with positive feedback received from patients and clinicians.
- **Initiated India's First international Clinical registry of 2000 patients** to evaluate performance and safety of RisoR Everolimus Eluting Stent System across India and Europe
- Signed two contract manufacturing contracts with companies based in US and Hong Kong in Vascular Access and Pain Management segment
- Established a wholly owned subsidiary in Brazil to expand presence; over the next few quarters we plan to expand our direct presence in this key South American market

Key Financial Highlights:

- Total Income grew by 10.7% in Q1 FY26 as compared to Q1 FY25, supported by strong Domestic performance
- Domestic operating revenue grew by 20.1% on a YoY basis, reflecting sustained traction in domestic market.
- Revenue from international market, which contributes approximately 70% of consolidated revenue, declined by 0.9%, impacted by short-term demand uncertainties due to on-going geopolitical tensions and tariff related headwinds
- Operating EBITDA margin stood at 26.3%
- Profit After Tax (PAT) increased by 25.5% in Q1 FY26 compared to Q1 FY25; PAT margin expanded by almost 250bps to 20.9% in Q1 FY26
- The company maintains a zero net debt position, with adequate liquidity of Rs. 1,248.6 Cr. as of 30th Jun'25
- Incurred a CAPEX of Rs. 95 Cr. in Q1 FY26 reflecting our commitment to create adequate infrastructure to capture future growth opportunities in the sector

Commenting on the results for the quarter, Mr. Himanshu Baid, Managing Director, Poly Medisure Limited stated:

We are pleased to share that we started the year on a steady note, with our Domestic revenue continuing to demonstrate strong growth momentum. This is supported by a healthy operating margin, enhanced PAT performance and significant product innovations—all while continuing to invest in sustainability, scale, and future capacity through R&D and green initiatives.

Our renal division continues to grow at a robust pace, and with the commercialization of our Critical Care and Cardiology division last year, we are further expanding our presence in the larger Medical Devices industry.

While short term challenges persist due to geopolitical tensions and recent tariff changes, we remain confident about the long term opportunity in for the Indian Medical Devices sector and continue to position ourselves strongly to capture that. We remain steadfast to our vision of *“Serving people through innovative healthcare solutions”*.

About Poly Medisure Limited:

Poly Medisure Ltd is a leading medical device manufacturer and exporter from India, with its products sold in over 125+ countries, making a significant global impact on healthcare. With a robust portfolio of over 200+ medical devices and more than 300+ patents, Polymed offers a comprehensive range of medical devices across 12 medical therapies, including infusion therapy, vascular access, dialysis and renal care, critical care, cardiology, oncology, transfusion, diagnostics, gastroenterology, anaesthesia and respiratory care, urology, and surgery and wound management. Supported by 12 state-of-the-art manufacturing facilities across 4 countries, Polymed has the capacity to produce over 1.8 billion medical devices annually, meeting the ever-growing global demand. The company's diverse product offering ensures it addresses a wide range of medical needs worldwide.

Disclaimer:

This press release contains forward-looking statements based on current expectations, assumptions, estimates, and projections about Poly Medicure Limited and its industry. These forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to differ materially include, but are not limited to, changes in economic conditions, competitive landscape, regulatory developments, and other risks detailed in the company's filings with regulatory authorities. Poly Medicure Limited undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

The financial information provided in this press release is unaudited and subject to change. Investors are advised to review the company's audited financial statements and other disclosures available on the company's website and through regulatory filings.

For more details, please contact:

Rahul Gautam

Investor Relations
investorcare@polymedicure.com

Hitesh Sardana,

Corporate Communication
hitesh.sardana@polymedicure.com